Optimizing HAP Therapy: Launch of a New Antibiotic Protocol
Optimizing HAP Therapy: Launch of a New Antibiotic Protocol
Authors:
Marianna Frazee, Jennifer Beavers, Robel Beyene, Jill Streams, Elizabeth Krebs
Body of Abstract:
Background: Hospital-acquired pneumonia (HAP) is common in trauma patients, making appropriate empiric antibiotic selection and de-escalation important for outcomes and resource use. Evidence suggests that per oral (PO) linezolid offers similar MRSA coverage to intravenous vancomycin with potential reductions in cost and medication-related complications. In August 2025, our Level 1 trauma center revised our practice management guideline (PMG) for antibiotic choice for patients with presumed HAP, recommending PO linezolid in place of IV vancomycin for empiric MRSA coverage. The new protocol also provided designated antibiotic de-escalation strategies based on clinical improvement metrics and respiratory culture results.
Aim: This study aimed to evaluate both protocol implementation and the impact of this new guideline on antibiotic stewardship, hypothesizing that the use of vancomycin and cefepime (as a marker of antipseudomonal antibiotic use) would decrease following protocol change.
Methods: A multidisciplinary team including surgeons, advanced practice providers, and pharmacists developed the new PMG. Education was provided at team-wide meetings and daily morning reports, with the guideline publicly available on our trauma website per our center’s standard practice. This study retrospectively compared patients treated for presumed HAP in the 3 months before and after protocol implementation. Demographics, antibiotic data, and outcomes were obtained via chart review and institutional trauma and infection registries. Data were compared using Wilcoxon rank sum and Chi-square analysis. Changes in vancomycin and cefepime utilization were also evaluated using a statistical process control (SPC) c-chart to detect variation over time and identify shifts following the intervention.
Results: A total of 82 trauma patients were treated for 102 episodes of presumed pneumonia, 55 before and 47 after guideline implementation. Protocol adherence exceeded 75% within three months of rollout. The SPC c-chart for vancomycin use demonstrated special cause variation after implementation, indicating a statistically meaningful shift in the process (Figure). Median days of vancomycin per pneumonia episode decreased in the post-implementation period (3 vs. 0, p<.01), while median days of cefepime prescribed were similar (4 vs. 5, p=0.18). There was no difference in rate of antibiotic de-escalation (54% vs. 63%, p=0.37.) Importantly, there were no adverse drug reactions noted during this early implementation period, and rates of antibiotic re-escalation remained similar (37% vs. 27%, p=0.43). Conclusions: Transitioning empiric HAP therapy from IV vancomycin/cefepime to PO linezolid/cefepime resulted in sustained reduction in vancomycin use, while the new de-escalation protocol did not significantly impact cefepime prescribing or de-escalation rates. This change in antibiotic regimen led to cost savings of approximately $6,200 in drug and lab costs over a 3-month period.
